|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
5/17/2012 7:52:18 AM
Three strikes and you’re out? In 2006, the FDA noticed that Acorda Therapeutics was having difficulty submitting serious and unexpected adverse even reports within 15 days of receiving such information as required by law. The same problem was observed during yet another inspection three years later. And when the FDA returned last summer, the agency found Acorda was still failing to report adverse events when required, according to a May 10 warning letter. Acorda, however, was not just a few days late. The FDA noted there were five reports that were submitted more than 100 days past the deadline. One report described a patient who died and was due to be filed with the agency on August 28, 2010, but not received until January 10, 2011, approximately 136 days late. Other side effects that should have been reported included irregular heartbeats, arrhythmia, acute fulminant hepatitis, hypersensitivity, and memory impairment.
|
|
|
|
|
|
|
|
|
|
|